（原标题：一脉阳光积极回应投资者关切：长期看好公司发展前景 回购+增持彰显坚定信心） 一脉阳光随后公布，有意不时于公开市场进一步购回H股，购回金额累计不超过2亿港元。据悉，本次 回购决定是基于其对集团近期在区域性医学影像共享中心、医学影像数据服务等业务领域所取得的阶段 性发展成果，以及集团在打造"数据+AI/算法+应用场景"的智慧医学影像全产业链领域所展现的专业能 力及研发技术的高度肯定。回购计划的实施不仅有利于稳定股价及提升股东回报，也彰显了一脉阳光对 自身股价以及公司未来长期发展的坚定信心。 一脉阳光同时还宣布，基于对公司整体发展前景及增长潜力的信心，为促进公司持续、稳定、健康发 展，维护广大公众投资者利益，公司董事长、执行董事兼行政总裁陈朝阳2025年12月8日在公开市场上 按每股10.10港元的平均价格以总代价600,950港元购入59,500股公司H股，占公司已发行股份总数的约 0.01%。增持股份后，其持股比例升至14.48%。 国内医学影像龙头企业一脉阳光(2522.HK)昨日连发三则公告，今日盘前公司高管再度进行交流回复， 积极回应投资者关切。 对于近期股价波动，一脉阳光公开回应称：公司经营一 ...

Core Viewpoint - The stock of Yipai Yangguang (2522.HK) has experienced a significant increase, rising over 11% in the last three trading days, driven by insider buying and positive developments in its business sectors [1] Group 1: Stock Performance - Yipai Yangguang's stock opened high today, reaching a peak increase of 4.4% to HKD 16.62 [1] - The stock has seen a cumulative rise of over 11% over the past three trading days [1] Group 2: Insider Buying - Company directors, including the Chairman and CEO Chen Chaoyang, purchased a total of 96,500 shares of the company's H-shares using personal funds on November 3 and 4, 2025 [1] - The decision for this increase in shareholding is based on the directors' confidence in the company's recent achievements in regional medical imaging sharing centers and data services [1] Group 3: Business Development and Strategic Alignment - The company has demonstrated strong capabilities in the "data + AI/algorithm + application scenario" full industry chain of smart medical imaging, which has been positively recognized [1] - The company's strategic layout in innovation aligns well with the State Council's implementation opinions on promoting and regulating the application of "AI + healthcare" issued on November 4, 2025 [1] - Directors believe that the current H-share price does not fully reflect the long-term investment value of the company [1]

Core Viewpoint - The company, Yipai Yangguang (02522), announced that several directors purchased a total of 96,500 H-shares in the open market, reflecting their confidence in the company's recent developments in medical imaging and AI applications [1] Group 1: Director Purchases - The chairman and CEO, Mr. Chen Chaoyang, along with other executive directors, purchased a total of 96,500 H-shares on November 3 and 4, 2025 [1] - The directors indicated that their decision to increase their holdings was based on the company's recent achievements in regional medical imaging sharing centers and data services [1] Group 2: Strategic Alignment and Confidence - The company's strategic layout in innovative fields aligns well with the State Council's recent implementation opinions on promoting and regulating AI in healthcare, issued on November 4, 2025 [1] - The directors expressed strong confidence in the company's future development prospects, believing that the current H-share price does not fully reflect the long-term investment value of the group [1] Group 3: Compliance and Public Holdings - The company maintains sufficient public shareholding as per the regulations of the Hong Kong Stock Exchange, even after the recent share purchases by the directors [1]